Key statistics
On Monday, Verve Therapeutics Inc (VERV:NSQ) closed at 11.23, -1.53% below its 52-week high of 11.41, set on Jun 17, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.27 |
---|---|
High | 11.33 |
Low | 11.17 |
Bid | 11.17 |
Offer | 11.29 |
Previous close | 11.30 |
Average volume | 5.84m |
---|---|
Shares outstanding | 89.14m |
Free float | 83.16m |
P/E (TTM) | -- |
Market cap | 1.01bn USD |
EPS (TTM) | -2.11 USD |
Data delayed at least 15 minutes, as of Jun 30 2025 21:00 BST.
More ▼
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics to Participate in Upcoming Investor Conferences
- Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
- Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
More ▼